In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Paul M Ridker
Speaker
Paul M Ridker
Paul M Ridker Paul M Ridker

Brigham and Women's Hospital, Boston (United States of America)

Specialities : Risk Factors and Prevention , Coronary Artery Disease Chronic, Echocardiography

Dr. Paul Ridker serves as the Eugene Braunwald Professor of Medicine ant the Harvard Medical School and as Director of the Center for Cardiovascular Disease Prevention at the Brigham and Women's Hospital, Boston, Massachusetts, USA. With research interests including inflammation biology, lipids, atherosclerosis, epidemiology, and prevention, Dr. Ridker has also designed and conducted a large number of multi-national trials funded by the NIH or industry including JUPITER, SPIRE-1, SPIRE-2, PREVENT, CANTOS, and CIRT. He currently is Co-Chair of the ongoing PROMINENT study.

27 presentations from this speaker

Beyond high intensity statin:drive LDL-C as low as you can - CON

Event : ESC Congress 2019

  • Session : Controversies in secondary prevention: treating residual risk
  • Speaker : PM Ridker (Boston,US)

Looking beyond CANTOS - Where will immune targeting bring us?

Event : ESC Congress 2019

  • Session : Targeting inflammation in cardiovascular disease - Is it feasible? And safe?
  • Speaker : PM Ridker (Boston,US)

Anti-inflammatory therapy : interleukin-1 beta inhibition to prevent cardiovascular events

Event : ESC Congress 2018

  • Session : Innovative strategies for secondary prevention
  • Speaker : PM Ridker (Boston,US)

Audience Q&A and panel discussion.

Event : ESC Congress 2018

  • Session : Emerging evidence-based approaches to reduce residual atherosclerotic risk
  • Speaker : W Koenig (Munich,DE), P Libby (Boston,US), PM Ridker (Boston,US), JH Cornel (Alkmaar,NL)
  • Sponsored by Novartis Pharma AG

Discussant review - FREED.

Event : ESC Congress 2018

  • Session : Hot Line Session 4
  • Speaker : PM Ridker (Boston,US)

Emerging evidence-based approaches to reduce residual atherosclerotic risk - ask the experts.

Event : ESC Congress 2018

  • Session : Emerging evidence-based approaches to reduce residual atherosclerotic risk - Ask the experts
  • Speaker : PM Ridker (Boston,US), A Catapano (Milan,IT)
  • Sponsored by Novartis Pharma AG

Looking back at CANTOS: what we have learned from CANTOS and subgroup analyses.

Event : ESC Congress 2018

  • Session : CANTOS one year after – A critical review: inflammation and CAD prevention
  • Speaker : PM Ridker (Boston,US)

Prevention 10 years from now - My predictions and how to get yourself ready.

Event : ESC Congress 2018

  • Session : Cardiology 10 years from now - My predictions and how to get yourself ready
  • Speaker : PM Ridker (Boston,US)

Therapeutic strategies for secondary cardiovascular disease prevention.

Event : ESC Congress 2018

  • Session : Emerging evidence-based approaches to reduce residual atherosclerotic risk
  • Speaker : PM Ridker (Boston,US)
  • Sponsored by Novartis Pharma AG

Audience Q&A - Atherosclerosis, cardiovascular risk factors and secondary prevention: are we making progress?

Event : ESC Congress 2017

  • Session : Atherosclerosis, cardiovascular risk factors and secondary prevention: are we making progress?
  • Speaker : W Koenig (Munich,DE), PM Ridker (Boston,US), TF Luscher (London,GB), P Libby (Boston,US)
  • Sponsored by Novartis Pharma AG

CANTOS - The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

Event : ESC Congress 2017

  • Session : Hot Line: Late-Breaking Clinical Trials 1
  • Speaker : PM Ridker (Boston,US)

Identifying appropriate patients to treat: a case-based approach.

Event : ESC Congress 2017

  • Session : PSCK9 inhibition: a new horizon in LDL-C management
  • Speaker : C Cannon (Boston,US), A Catapano (Milan,IT), SJ Nicholls (Adelaide,AU), PM Ridker (Boston,US), J Robinson (Iowa,US)
  • Sponsored by Sanofi and Regeneron

Inflammation plays a key role in coronary artery disease - PRO

Event : ESC Congress 2017

  • Session : Inflammation and cardiovascular disease
  • Speaker : PM Ridker (Boston,US)

Inflammation plays a key role in coronary artery disease - Rebuttal PRO.

Event : ESC Congress 2017

  • Session : Inflammation and cardiovascular disease
  • Speaker : PM Ridker (Boston,US)

Inflammatory processes in cardiovascular disease: a route to personalised medicine?

Event : ESC Congress 2017

  • Session : Inflammation and cardiovascular disease: the emerging role of 'omics'
  • Speaker : PM Ridker (Boston,US)

Learnings and clinical insights from SPIRE.

Event : ESC Congress 2017

  • Session : PSCK9 inhibition: a new horizon in LDL-C management
  • Speaker : PM Ridker (Boston,US)
  • Sponsored by Sanofi and Regeneron

Secondary cardiovascular disease prevention: what have we learnt from recent clinical trials?

Event : ESC Congress 2017

  • Session : Atherosclerosis and secondary cardiovascular disease prevention: inflammation and low density lipoprotein (LDL)-cholesterol
  • Speaker : PM Ridker (Boston,US)
  • Sponsored by Novartis Pharma AG

The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study.

Event : ESC Congress 2017

  • Session : Meet the Trialists - CANTOS
  • Speaker : PM Ridker (Boston,US)

A clinical perspective on PCSK9 inhibition: what do we know and what can we expect?

Event : ESC Congress 2016

  • Session : PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities
  • Speaker : PM Ridker (Boston,US)
  • Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by unrestricted educational grants from Amgen, Pfizer and Sanofi - Regeneron

Inflammation as potential target for therapy to target residual risk post ACS.

Event : ESC Congress 2016

  • Session : How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation
  • Speaker : PM Ridker (Boston,US)
  • Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by unrestricted educational grants from Novartis and Amgen

Accumulating clinical data on PCSK9 inhibition: what are the key lessons?

Event : ESC Congress 2015

  • Session : PCSK9 inhibition in lipid management: final steps towards implementation into clinical practice
  • Speaker : PM Ridker (Boston,US)
  • Organised by Academic Medical Center Amsterdam Course Director: John Kastelein Supported by an unrestricted educational grant from Physicians' Academy for Cardiovascular Education

Inflammation as target for therapy in atherothrombosis.

Event : ESC Congress 2015

  • Session : Cytokines and cardiovascular disease: exploring inflammation & clinical outcomes
  • Speaker : PM Ridker (Boston,US)
  • Organised by Academic Medical Center Amsterdam Course Director: John Kastelein Supported by an unrestricted educational grant from Physicians' Academy for Cardiovascular Education

An update on trials targeting inflammation: assessing new anti-inflammatory agents.

Event : ESC Congress 2014

  • Session : Managing inflammation in cardiovascular disease: debating the rationale for interventions
  • Speaker : PM Ridker (Boston,US)
  • Organised by Academic Medical Center Amsterdam / Course Director: John Kastelein / Supported by an unrestricted educational grant from Physicians’ Academy for Cardiovascular Education

Low-density lipoprotein and cardiovascular disease.

Event : ESC Congress 2014

  • Session : Lipids and cardiovascular disease
  • Speaker : PM Ridker (Boston,US)

Targeting inflammation in prevention of atherosclerotic events.

Event : ESC Congress 2013

  • Session : Inflammation & cardiovascular disease: exploring new options for intervention
  • Speaker : PM Ridker (Boston,US)
  • Organised by University College London / Course Director: Prof. John Deanfield / Supported by an unrestricted educational grant from Novartis

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are